Despite last month's pullback, shares of this medical device company that's aiming to revolutionize cancer treatment are up 126% over the last year.
News & Analysis: NovoCure
NVCR earnings call for the period ending December 31, 2018.
Recurring revenue, monopolistic market positions, and returns that tend to beat even the risky biotechs tie these three together.
Investors in the cancer-focused medical device company have enjoyed strong returns already. Is it too late to hop on board?
Align Technology, NovoCure, and DexCom look poised for explosive growth.
The biopharma stock had more than doubled from the beginning of 2018 to the end of September. Why are investors suddenly pessimistic?
Shares plunged after the company reported mixed quarterly results. Here are the must-know details for investors.
Shares of this medical device company that's aiming to revolutionize cancer treatment are up 123% in 2018.
Wall Street is excited about the growing potential for the company's cancer-fighting treatments.
Cryptocurrencies might grab all of the headlines, but these three businesses are better bets for the long term.